Vanguard Global Advisers
ACRV icon

Vanguard Global Advisers’s Acrivon Therapeutics ACRV Stock Holding History

Vanguard Global Advisers’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,453
Closed -$6.19K – 3640
2026
Q1 		$6.19K Buy
+4,453
New +$7.77K ﹤0.01% 3538

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Global Advisers's ACRV Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Acrivon Therapeutics (ACRV) in Q2 2026, closing a stake of 4,453 shares — an estimated $6.19K sold.

Vanguard Global Advisers first reported a position in ACRV in Q1 2026 and held it in 1 quarter. The position peaked at $6.19K in Q1 2026. 43 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Acrivon Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 4,453 Acrivon Therapeutics shares in Q2 2026, an estimated $6.19K.
  • Vanguard Global Advisers first reported a position in Acrivon Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Acrivon Therapeutics position peaked at $6.19K in Q1 2026.
  • 43 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.